Mirae Asset Global Investments Co. Ltd. Has $77,000 Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS)

Mirae Asset Global Investments Co. Ltd. increased its position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) by 26.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,357 shares of the company’s stock after purchasing an additional 280 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Keros Therapeutics were worth $77,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of KROS. Vanguard Group Inc. increased its holdings in Keros Therapeutics by 7.9% in the 1st quarter. Vanguard Group Inc. now owns 1,545,758 shares of the company’s stock valued at $102,329,000 after buying an additional 113,563 shares during the period. Darwin Global Management Ltd. increased its stake in Keros Therapeutics by 6.3% in the second quarter. Darwin Global Management Ltd. now owns 1,525,902 shares of the company’s stock valued at $68,772,000 after acquiring an additional 89,952 shares during the period. Price T Rowe Associates Inc. MD raised its position in Keros Therapeutics by 17.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,218,504 shares of the company’s stock worth $80,666,000 after purchasing an additional 176,803 shares in the last quarter. Redmile Group LLC acquired a new stake in Keros Therapeutics during the first quarter valued at approximately $36,576,000. Finally, Nantahala Capital Management LLC grew its stake in shares of Keros Therapeutics by 28.8% in the 2nd quarter. Nantahala Capital Management LLC now owns 378,807 shares of the company’s stock valued at $17,311,000 after purchasing an additional 84,810 shares during the period. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Keros Therapeutics

In other news, Director Carl L. Gordon sold 250,000 shares of the firm’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $44.01, for a total value of $11,002,500.00. Following the transaction, the director now directly owns 119,522 shares in the company, valued at $5,260,163.22. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 22.90% of the company’s stock.

Keros Therapeutics Trading Up 0.0 %

Shares of KROS stock opened at $59.95 on Tuesday. The firm’s 50 day moving average is $56.53 and its 200-day moving average is $51.86. Keros Therapeutics, Inc. has a 1 year low of $27.31 and a 1 year high of $73.00. The firm has a market capitalization of $2.25 billion, a price-to-earnings ratio of -11.69 and a beta of 1.23.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Wednesday, August 7th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.02). The business had revenue of $0.04 million for the quarter. Keros Therapeutics had a negative net margin of 62,012.55% and a negative return on equity of 44.73%. During the same quarter in the previous year, the firm posted ($1.27) EPS. On average, equities research analysts forecast that Keros Therapeutics, Inc. will post -4.9 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently commented on KROS shares. Cantor Fitzgerald initiated coverage on Keros Therapeutics in a research report on Thursday, October 24th. They set an “overweight” rating for the company. Guggenheim began coverage on shares of Keros Therapeutics in a research note on Monday, September 23rd. They issued a “buy” rating and a $96.00 target price on the stock. Scotiabank started coverage on shares of Keros Therapeutics in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $77.00 target price for the company. Finally, Bank of America reduced their price target on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a research report on Thursday, September 12th. Eleven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Keros Therapeutics has an average rating of “Buy” and an average target price of $89.11.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.